Oveporexton Met Primary, Key Secondary End Points in Phase 3 Studies

Oveporexton met its primary and key secondary endpoints in two phase 3 trials, significantly improving wakefulness, reducing cataplexy, and enhancing quality of life in narcolepsy type 1 patients. The drug shows a consistent safety profile with mainly mild to moderate side effects and represents a new treatment approach targeting the root cause of the disease.

This Wire brief sits within Fusion42's coverage of Drug Discovery.